Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Crystalline forms of brigatinib, pharmaceutical compositions comprising the same, and methods of their preparation and use of the same are disclosed herein.
1. Crystalline form A of brigatinib having the structure:
wherein the crystalline form has an x-ray powder diffraction pattern with peaks at 9.6, 17.2, 19.4, 20.1, 23.1, and 27.7°2θ, with a variance of ±0.2°2θ.
2. The crystalline form of claim 1 , having an x-ray powder diffraction pattern as shown in FIG. 2 .
3. The crystalline form of claim 1 , having an x-ray powder diffraction pattern with peaks at 6.1, 8.6, 9.6, 10.8, 11.3, 13.5, 14.3, 15.9, 17.2, 18.9, 19.4, 20.1, 21.8, 22.6, 23.1, 23.9, and 27.7°2θ, with a variance of ±0.2°2θ.
4. A pharmaceutical composition comprising the crystalline form of brigatinib of claim 1 and at least one component chosen from pharmaceutically acceptable carriers, pharmaceutically acceptable vehicles, and pharmaceutically acceptable excipients.
5. A method for treating non-small cell lung cancer in a subject in need thereof comprising administering to the subject the crystalline form of brigatinib of claim 1 .
6. The method of claim 5 , wherein the non-small cell lung cancer is ALK-positive non-small cell lung cancer.
7. The method of claim 6 , wherein the non-small cell lung cancer is ALK-positive metastatic non-small cell lung cancer.
8. The method of claim 7 , wherein the subject has been previously treated with crizotinib.